Three Months Ended June 30,

Six Months Ended June 30,

2025

2024

2025

2024

Operating Expenses

Late-stage development

$

27,115

$

28,765

$

55,212

$

56,057

Early-stage, preclinical and discovery programs

10,039

5,562

19,817

12,082

R&D personnel related

14,568

10,844

29,442

21,524

Research and development software, facilities and other strategic support

4,907

3,836

9,332

7,057

Other operational infrastructure and advisory support

8,582

4,762

15,693

9,461

Stock-based compensation expense

9,716

10,012

19,724

19,405

Depreciation expense

655

606

1,295

1,205

Interest income

(2,373

)

(5,393

)

(5,325

)

(9,450

)

Interest expense

314

—

314

—

Other expense (income), net

6

(44

)

11

(43

)

Segment net loss and consolidated net loss

$

73,529

$

58,950

$

145,515

$

117,298